LONDON, Nov 22 (Reuters) - Reckitt Benckiser Group has hired Morgan Stanley to advise on its options for its shrinking pharmaceuticals unit, according to two sources familiar with the matter.
SEC filings for any news related to the fact that Reckitt Benckiser Pharmaceuticals (RBP) has sued BDSI for filing ..... Background: About RBP: It's a part of ~$46B Reckitt Benckiser Group Plc ( OTC:RBGPY ), a manufacturer and marketer
Reckitt Benckiser ( RBGPF +6.1% ) — which turned in Q3 results Tuesday that beat analyst expectations — may look to sell its pharmaceutical
Reckitt Benckiser ’s third-quarter sales update showcased modest top-line underlying growth (3% in total, 5% excluding the pharmaceuticals
LONDON, Oct 22 (Reuters) - Reckitt Benckiser Group is exploring options for its prescription drug business independently of any other strategic projects it may be undertaking, Chief Executive Rakesh Kapoor said on Tuesday.
LONDON (Reuters) - Consumer goods group Reckitt Benckiser is reviewing options for its pharmaceuticals unit, it said on Tuesday, effectively putting up for sale its prescription medicine for heroin addiction, which faces cheap, copycat competition.
* Shares climb over 4.5 percent (Adds outlook, analyst estimates, background on pharma unit, byline)
A strong cold and flu season propped up Reckitt Benckiser 's RB . first-half results (underlying sales up 6% year over year) . However, adjusted operating margins slipped 80 basis points
Despite the ills faced by consumers, Reckitt Benckiser RB . actually benefited from the strong cold and flu season, as evidenced in its first-quarter trading update. Adjusting for acquisitions
In line with the plan laid out a year ago, Reckitt Benckiser ’s RB . focus on expanding in health and hygiene (particularly in emerging regions) is taking shape, supporting our narrow economic